Michael Davidson to Enzyme Inhibitors
This is a "connection" page, showing publications Michael Davidson has written about Enzyme Inhibitors.
Connection Strength
0.264
-
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
Score: 0.118
-
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
Score: 0.060
-
Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
Score: 0.048
-
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design. Pharmacoeconomics. 1997 Aug; 12(2 Pt 2):278-85.
Score: 0.027
-
Interaction of the adaptor protein Shc and the adhesion molecule cadherin. J Biol Chem. 1997 May 23; 272(21):13463-6.
Score: 0.007
-
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996 Jan 10; 275(2):128-33.
Score: 0.006